{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T16:22:02Z","timestamp":1780417322955,"version":"3.54.1"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T00:00:00Z","timestamp":1730246400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T00:00:00Z","timestamp":1730246400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Cardiovasc Drugs"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1007\/s40256-024-00692-y","type":"journal-article","created":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T16:17:10Z","timestamp":1730305030000},"page":"135-146","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Use of Direct Anticoagulants in Kidney Transplant Recipients: Review of the Current Evidence and Emerging Perspectives"],"prefix":"10.1007","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1369-3657","authenticated-orcid":false,"given":"Baris","family":"Afsar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rengin Elsurer","family":"Afsar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasar","family":"Caliskan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krista L.","family":"Lentine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,30]]},"reference":[{"issue":"5","key":"692_CR1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0285412","volume":"18","author":"C Firth","year":"2023","unstructured":"Firth C, Shamoun F, Apolinario M, Lim ES, Zhang N, Keddis MT. Safety and mortality outcomes for direct oral anticoagulants in renal transplant recipients. PLoS ONE. 2023;18(5): e0285412.","journal-title":"PLoS ONE"},{"issue":"6","key":"692_CR2","doi-asserted-by":"publisher","first-page":"e545","DOI":"10.1016\/j.chest.2021.07.055","volume":"160","author":"SM Stevens","year":"2021","unstructured":"Stevens SM, Woller SC, Kreuziger LB, et al. Antithrombotic therapy for VTE disease: second update of the CHEST guideline and expert panel report. Chest. 2021;160(6):e545\u2013608.","journal-title":"Chest"},{"issue":"10","key":"692_CR3","doi-asserted-by":"publisher","first-page":"3144","DOI":"10.1016\/j.transproceed.2020.02.171","volume":"52","author":"M Somaili","year":"2020","unstructured":"Somaili M, Jeyakumar N, McArthur E, et al. Incidence of direct oral anticoagulant prescriptions in kidney transplant recipients in Ontario, Canada. Transplant Proc. 2020;52(10):3144\u201352.","journal-title":"Transplant Proc"},{"issue":"2","key":"692_CR4","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1093\/ndt\/gfu323","volume":"30","author":"CR Lenihan","year":"2015","unstructured":"Lenihan CR, Montez-Rath ME, Shen JI, et al. Correlates and outcomes of warfarin initiation in kidney transplant recipients newly diagnosed with atrial fibrillation. Nephrol Dial Transplant. 2015;30(2):321\u20139.","journal-title":"Nephrol Dial Transplant"},{"issue":"6","key":"692_CR5","doi-asserted-by":"publisher","first-page":"134","DOI":"10.5500\/wjt.v9.i6.134","volume":"9","author":"MA Bukhari","year":"2019","unstructured":"Bukhari MA, Al-Theaby A, Tawhari M, et al. Efficacy and safety of non-vitamin K antagonist oral anticoagulants post-kidney transplantation. World J Transplant. 2019;9(6):134\u201344.","journal-title":"World J Transplant"},{"key":"692_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.vph.2020.106682","volume":"130","author":"G Camporese","year":"2020","unstructured":"Camporese G, Bernardi D, Bernardi E, et al. Absence of interaction between rivaroxaban, tacrolimus and everolimus in renal transplant recipients with deep vein thrombosis or atrial fibrillation. Vasc Pharmacol. 2020;130: 106682.","journal-title":"Vasc Pharmacol"},{"issue":"10","key":"692_CR7","doi-asserted-by":"publisher","first-page":"2918","DOI":"10.1016\/j.transproceed.2021.09.042","volume":"53","author":"MF Zaitoun","year":"2021","unstructured":"Zaitoun MF, Sheikh ME, Faifi ASA, Mahedy AW, Nazer WE, El Hennawy HM. The use of non-vitamin K antagonist oral anticoagulants in post-kidney transplantation, single-center experience. Transplant Proc. 2021;53(10):2918\u201322.","journal-title":"Transplant Proc"},{"key":"692_CR8","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.ejim.2023.08.003","volume":"119","author":"F Santoro","year":"2024","unstructured":"Santoro F, Casanova A, Simone S, et al. Immunosuppressive therapy and oral anticoagulation in kidney transplant recipients: direct oral anticoagulants versus vitamin-k antagonists. Eur J Intern Med. 2024;119:71\u20137.","journal-title":"Eur J Intern Med"},{"issue":"7","key":"692_CR9","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1111\/tri.13599","volume":"33","author":"AL Bixby","year":"2020","unstructured":"Bixby AL, Shaikh SA, Naik AS, et al. Safety and efficacy of direct-acting oral anticoagulants versus warfarin in kidney transplant recipients: a retrospective single-center cohort study. Transpl Int. 2020;33(7):740\u201351.","journal-title":"Transpl Int"},{"issue":"12","key":"692_CR10","doi-asserted-by":"publisher","first-page":"2625","DOI":"10.1097\/TP.0000000000003168","volume":"104","author":"J Leon","year":"2020","unstructured":"Leon J, Sabbah L, Aubert O, et al. Efficacy and safety of direct oral anticoagulants in kidney transplantation: a single-center pilot experience. Transplantation. 2020;104(12):2625\u201331.","journal-title":"Transplantation"},{"issue":"2","key":"692_CR11","first-page":"49","volume":"41","author":"N Basic-Jukic","year":"2020","unstructured":"Basic-Jukic N, Furic-Cunko V, Juric I. Novel oral anticoagulants in renal transplant recipients: a retrospective cohort study. Pril (Makedon Akad Nauk Umet Odd Med Nauki). 2020;41(2):49\u201355.","journal-title":"Pril (Makedon Akad Nauk Umet Odd Med Nauki)"},{"issue":"12","key":"692_CR12","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.14474","volume":"35","author":"K Parker","year":"2021","unstructured":"Parker K, Chu J, Morton M, et al. Can direct oral anticoagulants be used in kidney transplant recipients? Clin Transplant. 2021;35(12): e14474.","journal-title":"Clin Transplant"},{"issue":"4","key":"692_CR13","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1161\/CIRCULATIONAHA.121.056355","volume":"145","author":"AP Carnicelli","year":"2022","unstructured":"Carnicelli AP, Hong H, Connolly SJ, et al. Direct oral anticoagulants versus warfarin in patients with atrial fibrillation: patient-level network meta-analyses of randomized clinical trials with interaction testing by age and sex. Circulation. 2022;145(4):242\u201355.","journal-title":"Circulation"},{"key":"692_CR14","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.ejim.2023.08.020","volume":"119","author":"I Kyriakoulis","year":"2024","unstructured":"Kyriakoulis I, Adamou A, Stamatiou I, et al. Efficacy and safety of direct oral anticoagulants vs vitamin K antagonists in patients with atrial fibrillation and end-stage renal disease on hemodialysis: A systematic review and meta-analysis. Eur J Intern Med. 2024;119:45\u201352.","journal-title":"Eur J Intern Med"},{"issue":"11","key":"692_CR15","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.1097\/TP.0000000000004195","volume":"106","author":"J Rimsans","year":"2022","unstructured":"Rimsans J, Sylvester K, Kim M, Connors JM, Gabardi S. A review of direct-acting oral anticoagulants and their use in solid organ transplantation. Transplantation. 2022;106(11):2143\u201354.","journal-title":"Transplantation"},{"issue":"1","key":"692_CR16","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1002\/phar.2485","volume":"41","author":"AL Bixby","year":"2021","unstructured":"Bixby AL, Lichvar AB, Salerno D, Park JM. Use of direct-acting oral anticoagulants in solid organ transplantation: a systematic review. Pharmacotherapy. 2021;41(1):28\u201343.","journal-title":"Pharmacotherapy"},{"issue":"16","key":"692_CR17","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1093\/eurheartj\/ehy136","volume":"39","author":"J Steffel","year":"2018","unstructured":"Steffel J, Verhamme P, Potpara TS, et al. The 2018 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J. 2018;39(16):1330\u201393.","journal-title":"Eur Heart J"},{"issue":"16","key":"692_CR18","doi-asserted-by":"publisher","first-page":"8531","DOI":"10.3390\/ijms22168531","volume":"22","author":"G Grze\u015bk","year":"2021","unstructured":"Grze\u015bk G, Rogowicz D, Wo\u0142owiec \u0141, et al. The clinical significance of drug-food interactions of direct oral anticoagulants. Int J Mol Sci. 2021;22(16):8531.","journal-title":"Int J Mol Sci"},{"issue":"15","key":"692_CR19","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1161\/CIRCULATIONAHA.118.035418","volume":"138","author":"KC Siontis","year":"2018","unstructured":"Siontis KC, Zhang X, Eckard A, et al. Outcomes associated with apixaban use in patients with end-stage kidney disease and atrial fibrillation in the United States. Circulation. 2018;138(15):1519\u201329.","journal-title":"Circulation"},{"issue":"3","key":"692_CR20","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.14513","volume":"36","author":"J Zakko","year":"2022","unstructured":"Zakko J, Ganapathi AM, Whitson BA, et al. Safety of direct oral anticoagulants in solid organ transplant recipients: a meta-analysis. Clin Transplant. 2022;36(3): e14513.","journal-title":"Clin Transplant"},{"issue":"6","key":"692_CR21","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/j.semnephrol.2018.08.006","volume":"38","author":"A Hu","year":"2018","unstructured":"Hu A, Niu J, Winkelmayer WC. Oral anticoagulation in patients with end-stage kidney disease on dialysis and atrial fibrillation. Semin Nephrol. 2018;38(6):618\u201328.","journal-title":"Semin Nephrol"},{"issue":"3","key":"692_CR22","doi-asserted-by":"publisher","first-page":"279","DOI":"10.3390\/ph14030279","volume":"14","author":"R Vio","year":"2021","unstructured":"Vio R, Proietti R, Rigato M, Cal\u00f2 LA. Clinical evidence for the choice of the direct oral anticoagulant in patients with atrial fibrillation according to creatinine clearance. Pharmaceuticals (Basel). 2021;14(3):279.","journal-title":"Pharmaceuticals (Basel)"},{"issue":"6","key":"692_CR23","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1111\/bcp.14227","volume":"86","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, Souverein PC, Gardarsdottir H, van den Ham HA, Maitland-van der Zee AH, de Boer A. Risk of major bleeding among users of direct oral anticoagulants combined with interacting drugs: a population-based nested case\u2013control study. Br J Clin Pharmacol. 2020;86(6):1150\u201364.","journal-title":"Br J Clin Pharmacol"},{"issue":"12","key":"692_CR24","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.14396","volume":"35","author":"DM Salerno","year":"2021","unstructured":"Salerno DM, Thornberg ME, Lange NW, et al. Less bleeding associated with apixaban versus other direct acting oral anticoagulation in solid organ transplant recipients. Clin Transplant. 2021;35(12): e14396.","journal-title":"Clin Transplant"},{"key":"692_CR25","first-page":"179","volume":"6","author":"C Frost","year":"2014","unstructured":"Frost C, Song Y, Barrett YC, et al. A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban. Clin Pharmacol. 2014;6:179\u201387.","journal-title":"Clin Pharmacol"},{"issue":"4","key":"692_CR26","doi-asserted-by":"publisher","first-page":"259","DOI":"10.2165\/11318170-000000000-00000","volume":"49","author":"J Stangier","year":"2010","unstructured":"Stangier J, Rathgen K, St\u00e4hle H, Mazur D. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study. Clin Pharmacokinet. 2010;49(4):259\u201368.","journal-title":"Clin Pharmacokinet"},{"issue":"9","key":"692_CR27","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.2215\/CJN.01570213","volume":"8","author":"T Singh","year":"2013","unstructured":"Singh T, Maw TT, Henry BL, et al. Extracorporeal therapy for dabigatran removal in the treatment of acute bleeding: a single center experience. Clin J Am Soc Nephrol. 2013;8(9):1533\u20139.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"692_CR28","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1097\/FTD.0000000000000356","volume":"39","author":"T Vanhove","year":"2017","unstructured":"Vanhove T, Spriet I, Annaert P, et al. Effect of the direct oral anticoagulants rivaroxaban and apixaban on the disposition of calcineurin inhibitors in transplant recipients. Ther Drug Monit. 2017;39(1):77\u201382.","journal-title":"Ther Drug Monit"},{"key":"692_CR29","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.12873","author":"DM Salerno","year":"2017","unstructured":"Salerno DM, Tsapepas D, Papachristos A, et al. Direct oral anticoagulant considerations in solid organ transplantation: a review. Clin Transplant. 2017. https:\/\/doi.org\/10.1111\/ctr.12873.","journal-title":"Clin Transplant"},{"issue":"8","key":"692_CR30","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1093\/ajhp\/zxz013","volume":"76","author":"S Zochert","year":"2019","unstructured":"Zochert S, Oltman KM, Elgersma BM, Hellwig TR, Gulseth MP. Use of specific anti-Xa levels in acute kidney injury to transition patients from oral factor Xa inhibitors to i.v. heparin infusion. Am J Health Syst Pharm. 2019;76(8):505\u201311.","journal-title":"Am J Health Syst Pharm"},{"issue":"4","key":"692_CR31","doi-asserted-by":"publisher","first-page":"318","DOI":"10.23736\/S0375-9393.22.16254-1","volume":"88","author":"FH Saner","year":"2022","unstructured":"Saner FH, Stern S, Gallinat A, Minor T, Paul A. Kidney transplantation in a patient taking a direct oral anticoagulant. Minerva Anestesiol. 2022;88(4):318\u20139.","journal-title":"Minerva Anestesiol"},{"issue":"19","key":"692_CR32","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.2174\/1381612825666190709220449","volume":"25","author":"M Lamperti","year":"2019","unstructured":"Lamperti M, Khozenko A, Kumar A. Perioperative management of patients receiving new anticoagulants. Curr Pharm Des. 2019;25(19):2149\u201357.","journal-title":"Curr Pharm Des"},{"issue":"9","key":"692_CR33","doi-asserted-by":"publisher","first-page":"2389","DOI":"10.1681\/ASN.2021060814","volume":"32","author":"E Heher","year":"2021","unstructured":"Heher E, Elias N. Addressing transplant candidacy when evaluating safety of direct oral anticoagulant agents in patients on hemodialysis. J Am Soc Nephrol. 2021;32(9):2389\u201390.","journal-title":"J Am Soc Nephrol"},{"issue":"12","key":"692_CR34","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1056\/NEJMoa1607887","volume":"375","author":"SJ Connolly","year":"2016","unstructured":"Connolly SJ, Milling TJ Jr, Eikelboom JW, et al. Andexanet alfa for acute major bleeding associated with Factor Xa inhibitors. N Engl J Med. 2016;375(12):1131\u201341.","journal-title":"N Engl J Med"},{"issue":"6","key":"692_CR35","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.13853","volume":"34","author":"AB Lichvar","year":"2020","unstructured":"Lichvar AB, Pierce DR, Salerno D, Klem P, Waldman G, Park JM. Utilization of direct-acting oral anticoagulation in solid organ transplant patients: a national survey of institutional practices. Clin Transplant. 2020;34(6): e13853.","journal-title":"Clin Transplant"},{"issue":"8","key":"692_CR36","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1093\/ndt\/gfx265","volume":"33","author":"J Malyszko","year":"2018","unstructured":"Malyszko J, Lopatowska P, Mlodawska E, Musialowska D, Malyszko JS, Tomaszuk-Kazberuk A. Atrial fibrillation in kidney transplant recipients: is there a place for the novel drugs? Nephrol Dial Transplant. 2018;33(8):1304\u20139.","journal-title":"Nephrol Dial Transplant"},{"issue":"11","key":"692_CR37","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1016\/j.jacc.2014.05.065","volume":"64","author":"A Cuker","year":"2014","unstructured":"Cuker A, Siegal DM, Crowther MA, Garcia DA. Laboratory measurement of the anticoagulant activity of the non-vitamin K oral anticoagulants. J Am Coll Cardiol. 2014;64(11):1128\u201339.","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"692_CR38","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1373\/clinchem.2012.198788","volume":"59","author":"TA Helin","year":"2013","unstructured":"Helin TA, Pakkanen A, Lassila R, Joutsi-Korhonen L. Laboratory assessment of novel oral anticoagulants: method suitability and variability between coagulation laboratories. Clin Chem. 2013;59(5):807\u201314.","journal-title":"Clin Chem"},{"issue":"10","key":"692_CR39","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1093\/europace\/euab065","volume":"23","author":"J Steffel","year":"2021","unstructured":"Steffel J, Collins R, Antz M, et al. 2021 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Europace. 2021;23(10):1612\u201376.","journal-title":"Europace"},{"issue":"12","key":"692_CR40","doi-asserted-by":"publisher","first-page":"2228","DOI":"10.1093\/ndt\/gft380","volume":"29","author":"M Ryan","year":"2014","unstructured":"Ryan M, Ware K, Qamri Z, et al. Warfarin-related nephropathy is the tip of the iceberg: direct thrombin inhibitor dabigatran induces glomerular hemorrhage with acute kidney injury in rats. Nephrol Dial Transplant. 2014;29(12):2228\u201334.","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"692_CR41","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1002\/jcph.21","volume":"53","author":"M Zaleski","year":"2013","unstructured":"Zaleski M, Dabage N, Paixao R, Muniz J. Dabigatran-induced hyperkalemia in a renal transplant recipient: a clinical observation. J Clin Pharmacol. 2013;53(4):456\u20138.","journal-title":"J Clin Pharmacol"},{"issue":"2","key":"692_CR42","doi-asserted-by":"publisher","first-page":"278","DOI":"10.2215\/CJN.02170218","volume":"14","author":"N Jain","year":"2019","unstructured":"Jain N, Reilly RF. Clinical pharmacology of oral anticoagulants in patients with kidney disease. Clin J Am Soc Nephrol. 2019;14(2):278\u201387.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"692_CR43","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1681\/ASN.2019060579","volume":"31","author":"AS De Vriese","year":"2020","unstructured":"De Vriese AS, Caluw\u00e9 R, Pyfferoen L, et al. Multicenter randomized controlled trial of vitamin K antagonist replacement by rivaroxaban with or without vitamin K2 in hemodialysis patients with atrial fibrillation: the Valkyrie Study. J Am Soc Nephrol. 2020;31(1):186\u201396.","journal-title":"J Am Soc Nephrol"}],"container-title":["American Journal of Cardiovascular Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-024-00692-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40256-024-00692-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-024-00692-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T08:07:27Z","timestamp":1739174847000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40256-024-00692-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,30]]},"references-count":43,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["692"],"URL":"https:\/\/doi.org\/10.1007\/s40256-024-00692-y","relation":{},"ISSN":["1175-3277","1179-187X"],"issn-type":[{"value":"1175-3277","type":"print"},{"value":"1179-187X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,30]]},"assertion":[{"value":"10 October 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Both figures were created in Biorender.com.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Acknowledgement"}},{"value":"No external funding was used in the preparation of this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Baris Afsar, Rengin Elsurer Afsar, Yasar Caliskan, and Krista L Lentine declare that they have no potential conflicts of interest that might be relevant to the contents of this manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Data sharing is not applicable to this manuscript as no datasets were generated.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and materials"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Data extraction, writing: BA. Writing: BA, YC: Reviewing and editing: KLL: reviewing,  editing, and supervision. REA reviewing' editing and prepeartion of figures.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contribution"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Not applicable.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":10,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}